Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)

Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)

Background: Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand binding to EGFR and HER3, inhibits signaling from all ligand-dependent HER dimers, and can elicit antibody dependent cell mediated cytotoxicity. High tumor-expression of neuregulin 1 (NRG1), a ligand to HER3, m...

Full description

Bibliographic Details
Main Authors: Jérôme FAYETTE, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Danny Rischin, Christopher Nutting, Paul M. Harari, Tibor Csoszi, Dana Cernea, Paul O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan Baptist Vermorken
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-10-01
Series:Frontiers in Oncology
Subjects:
EGFR
HPV
cetuximab
HER3
Nrg1
SCCHN
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00232/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00232/full

Similar Items